CSL Limited

The Business

CSL earns close to three-quarters of group revenue from CSL Behring, its immunoglobulin (Ig) franchise, plasma-derived proteins used to treat immune deficiencies and neurological conditions. Behring's edge comes from owning the entire supply chain: over 300 plasma collection centres feeding proprietary fractionation plants, a structure new entrants cannot replicate quickly. CSL Seqirus makes influenza vaccines (roughly 13% of revenue), and CSL Vifor sells kidney and iron-deficiency treatments (around 15% and shrinking). Vifor is the problem child: generic competition and a looming reimbursement cliff are eroding its revenue base.

Recent Performance

FY26 revenue grew just 1.5% to A$15.8b, a soft headline that masks a stronger second half: Ig sales grew 7% in constant currency in the back half, against a weak first-half base hit by inventory destocking and one-off Medicare and China policy effects. Two guidance downgrades during the year, plus a A$7.1b impairment against Vifor, dented market confidence and triggered a de-rating from the stock's historical premium multiple.

Outlook

We expect group revenue to grow around 2.5% annually over the next decade, with Behring carrying the load at mid-single-digit growth as the Ig recovery consolidates, while Vifor continues to shrink toward a low base over the coming years. Earnings per share growth should accelerate over the next few years as cost-transformation savings, already running ahead of the internal A$550m multi-year target, offset the drag from Vifor's decline. Margins should hold broadly steady near 33-34% at the EBITDA line through the explicit forecast period, before fading as competitive dynamics normalise over the long run.

Key Risks

The largest tail risk is the emergence of a regulatory pathway for an Ig biosimilar. The probability is low, because no credible synthetic or biosimilar technology currently exists for plasma-derived proteins, but the impact would be severe and would directly challenge the moat assumption underpinning the franchise. A second risk is that Vifor's iron and nephrology business erodes faster than the guided decline, particularly with a key reimbursement mechanism (TDAPA) expiring in December 2026. A third is further US healthcare reimbursement reform, relevant given roughly half of group revenue is US-sourced and policy risk under a new administration remains a live threat.

What to Watch

The thesis-defining event is the FY27 first-half result in February 2027, which will confirm whether the second-half FY26 Ig recovery (+7% CC) is durable or was a one-off snap-back from a depressed base.

• Feb 2027 FY27 1H results — confirms or challenges the Ig growth recovery narrative.
• By Dec 2026 Permanent CEO appointment — resolves an overhang that has persisted for six months.

Company Description

CSL Behring is the core engine, contributing roughly 72% of group revenue from plasma-derived Ig products (PRIVIGEN, HIZENTRA) used to treat primary immune deficiencies and chronic neurological conditions. CSL Seqirus, around 13% of revenue, manufactures seasonal and pandemic influenza vaccines, holding a differentiated position through cell-based and adjuvanted formulations. CSL Vifor, roughly 15% of revenue and shrinking, sells iron-deficiency and nephrology (kidney disease) treatments, a business acquired in 2022 that has underperformed expectations. All three segments share centralised manufacturing infrastructure and a common R&D base.

Where the Growth Is

CSL Behring's immunoglobulin franchise is the growth engine. Second-half FY26 Ig sales grew 7% in constant currency, a clean recovery signal after a soft first half depressed by inventory destocking. We expect mid-single-digit Ig growth to persist through FY27 and beyond, supporting a group revenue compound annual growth rate near 2.5% over the coming decade, with Behring alone growing faster as Vifor's decline drags on the consolidated number.

Competitive Position

CSL's advantage rests on owning the plasma supply chain end to end, over 300 collection centres feeding proprietary fractionation facilities that extract multiple therapeutic proteins per litre of plasma. This vertical integration lets CSL run at a lower cost per litre than peers, a gap that has persisted for years and shows no sign of closing. The Ig market itself is concentrated among a handful of global players, which limits price competition, and CSL's largest direct competitor, Grifols, is currently financially distressed with elevated leverage, reducing near-term competitive pressure. We see this position holding for at least seven years, with no credible technology on the horizon that could replicate plasma-derived therapies synthetically within that window.

Management & Capital Discipline

Capital allocation over the past three years has been mixed. The A$7.1b Vifor impairment and a further A$590m write-off on a failed mRNA collaboration represent significant capital destruction, offset partially by disciplined share buybacks and a A$1.5b investment in expanding US manufacturing capacity at Kankakee. The board cut short-term incentive payouts to 3% of maximum this year, an unusually candid acknowledgment of underperformance for an ASX large-cap. That said, two guidance downgrades within twelve months and an unresolved permanent CEO search leave genuine questions about execution discipline that outweigh the goodwill from the board's transparency.

Financial Position

Net debt sits at around 1.8 times EBITDA, within CSL's target range of 1.5 to 2.0 times, and roughly 84% of debt carries a fixed rate, insulating the balance sheet from further rate rises. Operating cash flow of A$3.5b comfortably covers the dividend and growth capital expenditure. The balance sheet can absorb a moderate earnings shock without threatening the dividend or covenant headroom.